ArticleJournal of virology2008
An alphavirus replicon-based human metapneumovirus vaccine is immunogenic and protective in mice and cotton rats.
Article in Journal of virology, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
28 citing papers in PubMed, 58 citations in OpenAlex.
- Replicon RNA vaccines: design, delivery, and immunogenicity in infectious diseases and cancer.Journal of hematology & oncology · 2025Review
- A chimeric influenza virus vaccine expressing fusion protein epitopes induces protection from human metapneumovirus challenge in mice.Frontiers in microbiology · 2022Article
- Sendai Virus-Vectored Vaccines That Express Envelope Glycoproteins of Respiratory Viruses.Viruses · 2021Review
- The role of M2-2 PDZ-binding motifs in pulmonary innate immune responses to human metapneumovirus.Journal of medical virology · 2020Article
- Prospects of and Barriers to the Development of Epitope-Based Vaccines against Human Metapneumovirus.Pathogens (Basel, Switzerland) · 2020Review
- Human Metapneumovirus: A Largely Unrecognized Threat to Human Health.Pathogens (Basel, Switzerland) · 2020Article
- Vaccines for the Paramyxoviruses and Pneumoviruses: Successes, Candidates, and Hurdles.Viral immunology · 2018Review
- Human metapneumovirus - what we know now.F1000Research · 2018Review
- Article
- Article
- Immune Response to Human Metapneumovirus Infection: What We Have Learned from the Mouse Model.Pathogens (Basel, Switzerland) · 2015Review
- Lung CD8+ T Cell Impairment Occurs during Human Metapneumovirus Infection despite Virus-Like Particle Induction of Functional CD8+ T Cells.Journal of virology · 2015Article
- New Approaches for Immunization and Therapy against Human Metapneumovirus.Clinical and vaccine immunology : CVI · 2015Review
- Recent vaccine development for human metapneumovirus.The Journal of general virology · 2015Review
- Structural insights into the human metapneumovirus glycoprotein ectodomain.Journal of virology · 2014Article
- Small Animal Models for Human Metapneumovirus: Cotton Rat is More Permissive than Hamster and Mouse.Pathogens (Basel, Switzerland) · 2014Article
- Human metapneumovirus virus-like particles induce protective B and T cell responses in a mouse model.Journal of virology · 2014Article
- Human metapneumovirus G protein is highly conserved within but not between genetic lineages.Archives of virology · 2013Article
- An alphavirus vector-based tetravalent dengue vaccine induces a rapid and protective immune response in macaques that differs qualitatively from immunity induced by live virus infection.Journal of virology · 2013Article
- Human metapneumovirus in adults.Viruses · 2013Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 4 institutions in 2 countries.
Funding
Abstract
Human metapneumovirus (hMPV) is a recently discovered paramyxovirus that causes upper and lower respiratory tract infections in infants, the elderly, and immunocompromised individuals worldwide. Here, we developed Venezuelan equine encephalitis virus replicon particles (VRPs) encoding hMPV fusion (F) or attachment (G) glycoproteins and evaluated the immunogenicity and protective efficacy of these vaccine candidates in mice and cotton rats. VRPs encoding hMPV F protein, when administered intranasally, induced F-specific virus-neutralizing antibodies in serum and immunoglobulin A (IgA) antibodies in secretions at the respiratory mucosa. Challenge virus replication was reduced significantly in both the upper and lower respiratory tracts following intranasal hMPV challenge in these animals. However, vaccination with hMPV G protein VRPs did not induce neutralizing antibodies or protect animals from hMPV challenge. Close examination of the histopathology of the lungs of VRP-MPV F-vaccinated animals following hMPV challenge revealed no enhancement of inflammation or mucus production. Aberrant cytokine gene expression was not detected in these animals. Together, these results represent an important first step toward the use of VRPs encoding hMPV F proteins as a prophylactic vaccine for hMPV.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.